RAS’s Cloak of Invincibility Slips at Last?

Slides:

Advertisements

Similar presentations

SOD1 Integrates Signals from Oxygen and Glucose to Repress Respiration Amit R. Reddi, Valeria C. Culotta Cell Volume 152, Issue 1, Pages (January.

Advertisements

Individualized Medicine from Prewomb to Tomb Eric J. Topol Cell Volume 157, Issue 1, Pages (March 2014) DOI: /j.cell Copyright.

What We Talk About When We Talk About Fat Evan D. Rosen, Bruce M. Spiegelman Cell Volume 156, Issue 1, Pages (January 2014) DOI: /j.cell

Origins of Metastatic Traits Sakari Vanharanta, Joan Massagué Cancer Cell Volume 24, Issue 4, Pages (October 2013) DOI: /j.ccr

Distribution of Human Embryonic Stem Cell Lines: Who, When, and Where Jennifer B. McCormick, Jason Owen-Smith, Christopher Thomas Scott Cell Stem Cell.

Tumor-Derived Jagged1 Promotes Osteolytic Bone Metastasis of Breast Cancer by Engaging Notch Signaling in Bone Cells Nilay Sethi, Xudong Dai, Christopher.

Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer Min Ni, Yiwen Chen, Elgene Lim, Hallie Wimberly, Shannon T. Bailey, Yuuki Imai,

C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells Roger R. Gomis, Claudio Alarcón, Cristina Nadal, Catherine.

Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell Volume.

Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia Tim C.P. Somervaille, Michael L. Cleary Cancer Cell.

The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes Tae-Min Kim, Peter W. Laird, Peter J. Park Cell Volume 155, Issue.

Human Brown Adipose Tissue Sven Enerbäck Cell Metabolism Volume 11, Issue 4, Pages (April 2010) DOI: /j.cmet Copyright © 2010.

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity Cai-Hong.

Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung Zvi Granot, Erik Henke, Elizabeth A. Comen, Tari A. King, Larry Norton, Robert Benezra.

Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm Thierry Soussi, Klas G. Wiman Cancer Cell Volume 12, Issue 4, Pages (October.

A Conditional Mouse Model of Synovial Sarcoma: Insights into a Myogenic Origin Malay Haldar, Jeffrey D. Hancock, Cheryl M. Coffin, Stephen L. Lessnick,

Oxygen Sensors at the Crossroad of Metabolism Julián Aragonés, Peter Fraisl, Myriam Baes, Peter Carmeliet Cell Metabolism Volume 9, Issue 1, Pages

Charles Swanton, Julian Downward Cancer Cell

We Contain Multitudes: The Protean Face of Retinoblastoma

Jochen G. Schneider, Joseph H. Nadeau Cell Metabolism

NF-κB: A Coordinator for Epigenetic Regulation by MLL

“Ring-Fencing” BRCA1 Tumor Suppressor Activity

Volume 21, Issue 3, Pages (March 2012)

Wild-Type RAS: Keeping Mutant RAS in CHK

Jens T. Siveke, Roland M. Schmid Cancer Cell

Accelerating drug discovery: Open source cancer cell biology?

Mutant p53 gain of function: The NF-Y connection

Erythropoietin Surprises: An Immune Saga

Platelets and Tumor Cells: A New Form of Border Control

Rethinking ALS: The FUS about TDP-43

Gerry P. Crossan, Juan I. Garaycoechea, Ketan J. Patel Cell Stem Cell

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

MDS Is a Stem Cell Disorder After All

“Ring-Fencing” BRCA1 Tumor Suppressor Activity

A Radical Role for p38 MAPK in Tumor Initiation

Ewa Paluch, Carl-Philipp Heisenberg Developmental Cell

Evaluation of Kras Gene Mutation and Copy Number in Thymic Carcinomas and Thymomas Hidefumi Sasaki, MD, PhD, Motoki Yano, MD, PhD, Yoshitaka Fujii, MD,

Coordinate Transcriptional Regulation by ERG and Androgen Receptor in Fusion- Positive Prostate Cancers Yu Chen, Charles L. Sawyers Cancer Cell Volume.

A New Link in the Chain from Amino Acids to mTORC1 Activation

Wilma Ziebuhr, Jörg Vogel Molecular Cell

Giulio Francia, Urban Emmenegger, Robert S. Kerbel Cancer Cell

Eukaryotic Transcription Activation: Right on Target

Erythropoietin Surprises: An Immune Saga

Characterizing the Killer Colorectal Carcinomas

Volume 152, Issue 1, (January 2013)

Branching Out for Detection of Type 2 Diabetes

Considering the critical interface between tumor cells and stromal cells in the search for targets for anticancer therapy Laurence Blavier, Yves A. DeClerck

Volume 15, Issue 1, Pages 5-11 (January 2008)

Proteins in Plant Brassinosteroid Signaling

Volume 21, Issue 3, Pages (March 2012)

Genome-Wide SNP Analysis in Cancer: Leukemia Shows the Way

MicroRNA-155 Function in B Cells

A common pathway for genetic events leading to pheochromocytoma

Selfish Stem Cells Compete with Each Other

Multiple Endocrine Neoplasia Type 2B and Hirschsprung’s Disease

To Infinium, and Beyond! Cancer Cell

Volume 10, Issue 3, Pages (September 2006)

All Roads Lead to the Ribosome

The TRIP from ULF to ARF Cancer Cell

There's a Time and a Place for MYCN

c-Raf in KRas Mutant Cancers: A Moving Target

Connecting with an Old Partner in a New Way

Ibrutinib Treatment of CLL: The Cancer Fights Back

Volume 12, Issue 6, Pages (December 2007)

Volume 148, Issue 1, (January 2012)

The Kras Mutational Spectra of Chemically Induced Lung Tumors in Different Inbred Mice Mimics the Spectra of KRAS Mutations in Adenocarcinomas in Smokers.

The Role of TET2 in Hematologic Neoplasms

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Presentation transcript:

RAS’s Cloak of Invincibility Slips at Last? Julian Downward Cancer Cell Volume 25, Issue 1, Pages 5-6 (January 2014) DOI: 10.1016/j.ccr.2013.12.016 Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 1 The Distribution of Mutations in KRAS Found in Human Cancers Ostrem et al. (2013) have targeted the cysteine 12 mutant, outlined in red, which accounts for about 12% of total KRAS mutations and is found in about 2% of all human cancers. Common KRAS mutations involve substitution of reactive amino acid side chains, which may be targetable by similar approaches, with the exception of valine and alanine at codon 12, marked here by horizontal crosshatches. Data derived from the COSMIC database (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). Cancer Cell 2014 25, 5-6DOI: (10.1016/j.ccr.2013.12.016) Copyright © 2014 Elsevier Inc. Terms and Conditions